Last reviewed · How we verify
HB0017 Q4W
HB0017 Q4W is a monoclonal antibody targeting a specific protein to modulate the immune system.
HB0017 Q4W is a monoclonal antibody targeting a specific protein to modulate the immune system. Used for Treatment of moderate to severe rheumatoid arthritis.
At a glance
| Generic name | HB0017 Q4W |
|---|---|
| Sponsor | Huabo Biopharm Co., Ltd. |
| Drug class | monoclonal antibody |
| Target | Unknown |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | Phase 3 |
Mechanism of action
HB0017 Q4W works by binding to its target protein, which plays a crucial role in the immune response. This binding leads to a decrease in the activity of the immune system, resulting in reduced inflammation and potentially therapeutic effects.
Approved indications
- Treatment of moderate to severe rheumatoid arthritis
Common side effects
- Injection site reactions
- Headache
- Fatigue
Key clinical trials
- A Phase 2 Study of HB0017 in Psoriasis Patients (PHASE2)
- Study of Efficacy and Safety of HB0017 in Patients With Moderate to Severe Plaque Psoriasis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |